课题基金 / 基金详情

Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant

Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant
高眼压治疗研究 20 年随访:协调中心拨款
批准号:
9755440
负责人:
MAE O GORDON
金额:
$118.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2022-06-30

项目摘要

项目成果

MAE O GORDON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Primary open-angle glaucoma (POAG) is one of the leading causes of blindness in the United States and many other nations and is the leading cause of blindness in African Americans. Elevated intraocular pressure (ocular hypertension or OHT) is a major risk factor for developing POAG and the only modifiable risk factor at present. 4-7% of the United States population above age 40 has OHT. A major public health issue is how to apply the principles of patient- centered care and manage this large group of people in an effective and cost-effective manner. The OHTS carefully followed OHT participants for a median of 13 years. (OHTS Phase 1 and 2) This includes 279 participants who developed POAG during the study, the largest inception cohort of POAG patients ever described. We propose to re-examine all surviving OHTS participants at 20 years or more in 2015-2017 (OHTS Phase 3). We will determine the incidence and severity of POAG in the OHTS cohort and determine the frequency and severity of self-reported functional limitations associated with POAG. We will also develop a 20-year prediction model for stratifying OHT patients by their risk of developing POAG and, among those who developed POAG, a prediction model for the rate of visual field loss. OHTS Phase 3 will allow us to develop evidence-based, 20-year guidelines for the management of patients with OHT. This will aid patients and clinicians to make informed decisions about the appropriate frequency of examinations and tests and the benefit of early, preventative treatment. Informed decisions should improve outcomes, reduce costs and reduce patient and clinician burden.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Long-Term Quality of Life in the Ocular Hypertension Treatment Study Cohort
  • 批准号:
    10667711
  • 项目类别:
  • 资助金额:
    $24.63万
  • 财政年份:
    2023
  • 负责人:
    MAE O GORDON
  • 依托单位:
Resubmission: Latent Class Trajectory Analysis in the OHTS Study
  • 批准号:
    10675764
  • 项目类别:
  • 资助金额:
    $23.33万
  • 财政年份:
    2022
  • 负责人:
    MAE O GORDON
  • 依托单位:
Resubmission: Latent Class Trajectory Analysis in the OHTS Study
  • 批准号:
    10540153
  • 项目类别:
  • 资助金额:
    $19.65万
  • 财政年份:
    2022
  • 负责人:
    MAE O GORDON
  • 依托单位:
Innovative Analytical Methods for Repeated Measures in the OHTS Study
  • 批准号:
    10219276
  • 项目类别:
  • 资助金额:
    $23.59万
  • 财政年份:
    2020
  • 负责人:
    MAE O GORDON
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: